Arnold S Monto
Overview
Explore the profile of Arnold S Monto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
232
Citations
10090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ibiebele J, Godonou E, Callear A, Smith M, Truscon R, Johnson E, et al.
Nat Commun
. 2025 Feb;
16(1):1249.
PMID: 39893197
The role of viral interaction-where one virus enhances or inhibits infection with another virus-in respiratory virus transmission is not well characterized. This study used data from 4029 total participants from...
2.
Huang P, Nowalk M, Zimmerman R, Olson S, Talbot H, Zhu Y, et al.
Hum Vaccin Immunother
. 2025 Jan;
21(1):2457205.
PMID: 39875316
Influenza causes 100,000-710,000 hospitalizations annually in the U.S. Patients with liver disease are at higher risk of severe outcomes following influenza infection. This study evaluated influenza vaccine effectiveness (VE) against...
3.
Feldstein L, Ruffin J, Wiegand R, Borkowf C, James-Gist J, Babu T, et al.
J Infect Dis
. 2025 Jan;
PMID: 39774936
Background: Understanding protection against SARS-CoV-2 infection by vaccine and hybrid immunity is important for informing public health strategies as new variants emerge. Methods: We analyzed data from three cohort studies...
4.
Feldstein L, Ruffin J, Wiegand R, Grant L, Babu T, Briggs-Hagen M, et al.
J Pediatric Infect Dis Soc
. 2024 Dec;
14(1.
PMID: 39656907
To understand how coronavirus disease 2019 vaccines impact infection risk in children <5 years, we assessed risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from September 2022 to...
5.
Leis A, Wagner A, Flannery B, Chung J, Monto A, Martin E
Vaccine
. 2024 Oct;
42(26):126493.
PMID: 39476473
Test-negative design (TND) studies are cornerstones of vaccine effectiveness (VE) monitoring for influenza. The introduction of SARS-CoV-2 and RSV vaccines complicate the analysis of this design, with control selection restriction...
6.
Fowlkes A, Peretz A, Greenberg D, Hirsch A, Martin E, Levine M, et al.
Int J Infect Dis
. 2024 Oct;
149:107260.
PMID: 39395753
Objectives: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent...
7.
Monto A, Foster-Tucker J, Callear A, Leis A, Godonou E, Smith M, et al.
J Infect Dis
. 2024 Aug;
PMID: 39179953
Background: Viral respiratory illnesses are the most common acute illnesses experienced and generally follow a predicted pattern over time. The SARS-CoV-2 pandemic interrupted that pattern. Methods: The HIVE (Household Influenza...
8.
Azziz-Baumgartner E, Hirsch A, Yoo Y, Peretz A, Greenberg D, Avni Y, et al.
Euro Surveill
. 2024 Aug;
29(31).
PMID: 39092531
BackgroundHealthcare personnel (HCP) are at high risk for respiratory infections through occupational exposure to respiratory viruses.AimWe used data from a prospective influenza vaccine effectiveness study in HCP to quantify the...
9.
Begley K, Leis A, Petrie J, Truscon R, Johnson E, Lamerato L, et al.
Clin Infect Dis
. 2024 Jun;
79(4):1039-1045.
PMID: 38836601
Background: Data on the true prevalence of respiratory syncytial virus (RSV) among medically attended acute respiratory illnesses (MAARI) has been limited by the lack of regular clinical testing of mild...
10.
King J, Chung J, Donahue J, Martin E, Leis A, Monto A, et al.
BMC Infect Dis
. 2024 Mar;
24(1):300.
PMID: 38454352
Background: Symptoms of COVID-19 including fatigue and dyspnea, may persist for weeks to months after SARS-CoV-2 infection. This study compared self-reported disability among SARS-CoV-2-positive and negative persons with mild to...